Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Lung Diseases × Vinorelbine × Clear all

Phase

Status

Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 30 Carcinoma, Non-Small-Cell Lung 14 Lung Neoplasms 9 Neoplasm Metastasis 3 Neoplasms 2 Hodgkin Disease 2 Adenocarcinoma of Lung 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Thoracic Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Recurrence 1 Pancreatic Neoplasms 1 Mesothelioma 1 Malignant Solid Tumour 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma 1 Lung Diseases 1 Breast Neoplasms, Male 1 Advanced Non-Small Cell Lung Cancer 1 Adenocarcinoma, Bronchiolo-Alveolar 1

Interventions

Pemetrexed 5 Carboplatin 5 pembrolizumab 2 osimertinib 2 Paclitaxel 2 Nivolumab 2 Gemcitabine 2 sitravatinib 1 pralsetinib 1 patritumab 1 atezolizumab 1 Vinorelbine 1 Patient Reported Outcome Measures 1 Natriuretic Peptide, Brain 1 Ipilimumab 1 Indocyanine Green 1 Erlotinib Hydrochloride 1 Cisplatin 1 Bevacizumab 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05583188 2024-07-19

VIGOR

Galvanize Therapeutics, Inc.

Phase 4 Terminated

Lung Diseases, Lung Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡